1. Home
  2. UNCY vs MSLE Comparison

UNCY vs MSLE Comparison

Compare UNCY & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Unicycive Therapeutics Inc.

UNCY

Unicycive Therapeutics Inc.

HOLD

Current Price

$6.63

Market Cap

145.3M

Sector

Health Care

ML Signal

HOLD

MSLE

Satellos Bioscience Inc. Common Stock

N/A

Current Price

$6.50

Market Cap

146.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
UNCY
MSLE
Founded
2016
N/A
Country
United States
Canada
Employees
N/A
17
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
145.3M
146.9M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
UNCY
MSLE
Price
$6.63
$6.50
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$38.00
N/A
AVG Volume (30 Days)
489.9K
109.7K
Earning Date
05-13-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$675,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$407.73
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.47
$5.50
52 Week High
$7.57
$13.39

Technical Indicators

Market Signals
Indicator
UNCY
MSLE
Relative Strength Index (RSI) 49.09 37.82
Support Level $6.48 $5.50
Resistance Level $7.12 $7.52
Average True Range (ATR) 0.42 0.59
MACD -0.01 0.12
Stochastic Oscillator 41.22 44.55

Price Performance

Historical Comparison
UNCY
MSLE

About UNCY Unicycive Therapeutics Inc.

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

About MSLE Satellos Bioscience Inc. Common Stock

Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Share on Social Networks: